GU Cancers Symposium: Atezolizumab Plus Bevacizumab in Advanced Kidney Cancer
Combining the immunotherapy atezolizumab with the targeted therapy bevacizumab delayed cancer growth by about 3 months longer than with sunitinib in previously untreated patients with PD-L1–positive metastatic renal cell carcinoma, according to the IMmotion151 trial. In addition, fewer treatment-related side effects were reported with the combination therapy. These phase III study findings will be presented at the upcoming 2018 Genitourinary Cancers Symposium in San Francisco by Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues (Abstract 578).
“For an aggressive cancer like this, we think a 3.5-month progression-free survival, given the tolerability for this new combination treatment regimen, is an important development,” declared Dr. Motzer.
A total of 915 adults were randomly assigned to receive either atezolizumab plus bevacizumab intravenously every 3 weeks or sunitinib orally daily for 4 weeks followed by 2 weeks off treatment. Of these patients, 362 had PD-L1–positive disease.
At a median follow-up of 15 months, those in the PD-L1–positive group treated with the combination therapy had a median progression-free survival of 11.2 months, compared with 7.7 months in the sunitinib group. In the intention-to-treat group, a more modest benefit of the combination therapy was reported. Overall survival data are still immature, but at this early interim analysis, the difference in overall survival between the two treatment regimens was not statistically significant. As for toxicity, there were fewer treatment-related side effects with the combination therapy than with sunitinib (40% vs. 54%).